← Compound index
COMPOUND RECORD / EPITHALAMIN

EpithalaminЭпиталамин

A pineal-gland extract containing a mixture of peptides, studied in human aging and melatonin research.

SleepLongevity
Source linked

What the studies found

Comparison in people · 2011

Epithalamin and 15-year follow-up in older adults with coronary disease

Alive at 15 years
26/39 (66.7%) vs 16/40 (40.0%)Epithalamin plus standard care versus standard care.
Deaths attributed to myocardial infarction or stroke
6/13 deaths vs 20/24 deathsCause-of-death counts among participants who died.

At 15 years, 26/39 patients in the Epithalamin group and 16/40 in the standard-care group were alive. This small historical comparison followed patients with coronary disease.

Study notes · methods, sources and limitations

Participants or model 79 older patients with coronary disease. Thirty-nine received adjunctive Epithalamin and 40 received standard care alone.

Design Reported randomized comparative follow-up from the Kyiv gerontology program with survival curves and cardiovascular outcomes.

Important limitations

  • Small historical comparison, with limited reporting about masking and subsequent treatment. The associated 12-year paper may share the same participants. Epithalamin is a pineal extract. The study did not administer synthetic Epitalon.

Bulletin of Experimental Biology and Medicine. 2011;151(3):366–369. PMID 22451889. · Publication record

Original source or citation ↗

Study results and tables ↗

Comparison in people · 2008

Epithalamin after complicated appendicitis

Study of multiple preparations

Mean hospitalization
18.0 ± 0.6 daysAdjunct sample: 12. Standard care: 24.2 ± 0.6 days (n = 10).
TNF-α before → after
486 ± 28 → 205 ± 19 pg/mL (n = 12)Within-group p < 0.001 in Table 3

In this small comparison, mean stay was 6.2 days shorter with Epithalamin plus standard care. The standard-care group averaged 24.2 days.

Author affiliations · Chita Medical Institute

Study notes · methods, sources and limitations

Participants or model 84 adults aged 18–42: 12 with uncomplicated appendicitis and 72 with postoperative wound infection. Of the 72, 62 received a peptide adjunct. Thirty healthy volunteers were a laboratory reference group.

Design Comparison of standard care and peptide adjuncts after postoperative wound infection. The paper measured serum cytokines by immunoassay and compared immune markers before and after treatment.

Important limitations

  • The study had small, unequal groups and unclear treatment assignment. The differences are unadjusted.
  • Small, unequal groups and unclear treatment assignment leave confounding unresolved. The article does not establish that Vilon was superior or equivalent to the other adjuncts. The Vilon hospital groups totaled 40. The cytokine table included 25, with no breakdown by treatment duration. The hospitalization paragraph prints p < 0.01 after each mean without clearly specifying a contrast. No systematic adverse-event table or quantified wound-healing rates were recovered.
  • Vilon showed the largest within-group TNF-α decrease. Hospitalization means were close among the four adjunct groups. Neither outcome establishes a comparative treatment effect.

Medical Immunology. 2008;10(4–5):455–462. · Original clinical journal article

Original source or citation ↗

Source for the reported results ↗

Study results and tables ↗

Animal research · 2012

Melatonin and pineal gland peptides are able to correct the impairment of reproductive cycles in rats

Study of multiple preparations

Epithalamin
Recovery of norepinephrine diurnal dynamics in medial preoptic areaNorepinephrine decreased between 09:30 and 11:00 circadian time
Epitalon
Dopamine remained low at 05:00 and increased by 11:00 circadian timeMedian eminence/arcuate region; no numerical concentrations supplied
Pregnancy and fertility outcomes
No pregnant cohort, congenital-anomaly rate or verified live-birth benefit in the abstract

Epithalamin reportedly restored hypothalamic norepinephrine rhythms, while Epitalon had a stronger dopamine-rhythm effect in another hypothalamic region. The experiment used 1,2-dimethylhydrazine, not a pregnancy model or a methionine-only intervention.

Study notes · methods, sources and limitations

Participants or model Nonpregnant female rats in a xenobiotic-induced reproductive-aging model; n absent from abstract

Design Single 1,2-dimethylhydrazine exposure in female rats; region- and circadian-time-specific catecholamine measurements after melatonin or pineal-peptide interventions.

Important limitations

  • Reproductive-cycle neurochemistry is not pregnancy-safety evidence or proof of improved human fertility.
  • Reproductive-cycle neurochemistry is not pregnancy-safety evidence or proof of improved human fertility. Epitalon is a defined tetrapeptide; Epithalamin is a bovine pineal peptide extract. Their findings are not interchangeable. Doses, n, allocation, quantitative effect sizes and adverse-event surveillance unavailable in the abstract.

Current aging science. 2012;5(3):178-85. PMID 23237594 · Original journal publication

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Epithalamin

Names in this research collection

Epithalamine

Organ-derived peptide research: clinical findings and lineage ↗

Research background

A pineal-gland tissue extract containing a mixture of peptides. Human aging and melatonin studies of this preparation must be distinguished from research on synthetic Epitalon (AEDG).

Pregnancy and offspring research

Epithalamin reportedly restored hypothalamic norepinephrine rhythms, while Epitalon had a stronger dopamine-rhythm effect in another hypothalamic region. The experiment used 1,2-dimethylhydrazine, not a pregnancy model or a methionine-only intervention.

Reproductive-cycle neurochemistry is not pregnancy-safety evidence or proof of improved human fertility.

Reported findings and methods ↗ · Pregnancy research: full evidence review and archive ↗

More study findings

Animal research · 2018

Original hypoxia, heat and cold results

Study of multiple preparations

Epithalamin · course hypoxia and cold
7.4±4.5 min at 10 mg/kg in hypoxia; 194±22 vs 168±12 min at 0.5 mg/kg in air coolingSeparate dose and stress protocols. 1 mg/kg hypoxia arm was unmarked.Both selected contrasts p<0.05 as marked
Publication overlap
2014 Table 11 and 2018 Table 1 repeat the same valuesCounts as one reported experiment. Both publications also describe a distinct acute mouse screen.

The 2014 and 2018 course-hypoxia tables repeat the same experiment.

Study notes · methods, sources and limitations

Participants or model Outbred male mice in the single-dose hypoxia screen; male rats (180–210 g) in the repeated-dose hypoxia table. Separate temperature experiments.

Design The single-dose mouse screen used 10,000 m, 8–10 per dose in the 2018 report (6–10 in the 2014 book). Table 1 instead reports a three-day rat series tested at 11,500 m the next day. Arm sizes for the repeated-dose table are not stated in the audited passage.

Important limitations

  • Separate mouse and rat protocols. Human performance was not assessed.
  • The 2018 rat course results and 2014 book table belong to one evidence family. The book omits an explicit course-series species and altitude in the adjacent paragraph. Short survival in an extreme animal model is separate from human endurance or safety.
  • The papers distinguish the single-dose mouse screen from the three-day rat protocol. The matching table adds no independent animals or human participants.

Biomeditsina 2018(2):4–14, Tables 1–3; paired with 2014 Volume III Table 11 · Biomeditsina 2018(2):4–14, Tables 1–3; paired with 2014 Volume III Table 11

Original source or citation ↗

Study results and tables ↗

Comparison in people · 2014

Single intranasal exposure at simulated altitude

Study of multiple preparations

Epithalamin · number of complaints
0.33±0.13 vs 1.4±0.5Authors marked a trend.p<0.1 versus saline

Table 12 compares four small peptide arms with saline at 4,500 m.

Study notes · methods, sources and limitations

Participants or model Men aged 20–25 with asthenic or immune-status features. Four active arms of 6–8 each and 11 saline controls.

Design Author-described random assignment. Exposure for 60–80 min at simulated 4,500 m with postural testing, a three-minute 100 W cycling load, motor tasks and blood measurements.

Important limitations

  • Participant overlap with the broader aerospace archive remains unresolved.
  • Small arms, numerous endpoints and several comparisons reported at p<0.1. Exact allocation counts and overlap with the Medilab lineage remain unresolved.
  • The 4,500 m protocol differs from Cheprasov’s 5,000 m comparison. Participant independence has not been established and this series adds no people to the historical tally.

Essays on Sports Pharmacology, Vol. III, Vectors of Pharmacoregulation, Chapter 7, pp. 177–180, Table 12 · Essays on Sports Pharmacology, Vol. III, Vectors of Pharmacoregulation, Chapter 7, pp. 177–180, Table 12

Original source or citation ↗

Study results and tables ↗

Comparison in people · 1997

Cheprasov’s Medilab peptide comparisons in aerospace stress

Study of multiple preparations

Hypobaric comparison
Thymalin: 15–20% higher work measures; Cortexin: 10–15% improvement in selected operator measuresAbstract narrative; full arm-level estimates unavailable.
Coriolis motion tolerance
Cortexin +89%, Thymogen +73%, Epithalamin +68%Reported tolerance-time improvement relative to control, ten per arm.
Sustained work
Author reported recovery of selected Thymogen-group measures to baseline by three hoursFour per arm. Cortexin and oral Bemitil plus sydnocarb were separate comparators.

The three test series covered hypoxia, motion tolerance and 24 hours of work. The abstract reports favorable task results for selected peptides and gives a tiny separate postflight Thymogen comparison.

More reported outcomes
Postflight respiratory infections
1 of 4 in Thymogen arm versus 4 of 4 salineReported during the following year, a descriptive count from four pairs.
Program headcount
328 stated; stage rows add to 338The 116 and 8 are subseries, with no additional headcount contributed to the historical tally.
Study notes · methods, sources and limitations

Participants or model 116 men across three stress comparisons (30, 70 and 16), plus an eight-cosmonaut comparison within the reported dissertation program of 328.

Design Hypobaric test: three arms of 10 at 5,000 m for 60 min. Motion: seven arms of 10 in a Coriolis test. Work: four arms of four at 50% of individually tolerated load. Postflight: four mission pairs, one participant per pair given Thymogen.

Reported study exposure
Hypoxia: intranasal Cortexin or Thymalin, 20 mg per course over two days, or placebo. Motion: single intranasal 5 mg Thymalin, Cortexin, Prostatilen or Epithalamin, or 50 µg Thymogen, with oral scopolamine 0.1 mg and placebo controls. Work: nasal Thymogen 100 µg or Cortexin 10 mg before work and after 6 and 12 h, or oral sydnocarb plus Bemitil, or saline. Postflight: intranasal Thymogen 100 µg/day for seven days.

Important limitations

  • Small comparisons, incomplete outcome reporting and unclear separation from related Medilab publications.
  • Small comparisons, incomplete outcome reporting and unclear separation from related Medilab publications. The 47 modeling experts were outside the participant table.
  • The aerospace findings concern separate stress and recovery tasks, with no reliable pooled treatment effect.

Kirov Military Medical Academy doctoral dissertation author abstract, Table 1 and methods · Kirov Military Medical Academy doctoral dissertation author abstract, Table 1 and methods

Original source or citation ↗

Study results and tables ↗

Animal research · 2006

Age and baseline anxiety in Lysenko’s peptide stress models

Study of multiple preparations

High-anxiety young rats
Vilon and GVS-111 were highlighted in the author’s conclusionsOriginal group-level numerical estimates and doses still need retrieval.
Stress-response direction
Favorable and unfavorable responses describedThe author discusses this for GVS-111 and an experimental preparation called NKT. NKT identity remains unresolved.

The author reported that the direction of peptide-associated changes depended on age and baseline anxiety. Some shifts were unfavorable.

Study notes · methods, sources and limitations

Participants or model Rats grouped by age and baseline anxiety; series-specific denominators remain unverified.

Design Hypokinesia, hypoxia and exertion models, with behavioral, immune and oxidative endpoints. Twenty-four-hour hypokinesia was one stress protocol.

Important limitations

  • Potential overlap with narrower author-network dissertations, including Morgul and Rudenko. Outcomes cannot be pooled or assigned to humans.
  • A mechanistic program on stress response. The dissertation-level conclusion does not isolate all preparation-specific effects.

Doctoral dissertation, 244 pp., introduction and conclusions · Doctoral dissertation, 244 pp., introduction and conclusions

Original source or citation ↗

Study results and tables ↗

Animal research · 2004

Epithalamin under exercise and restricted movement in younger and older rats

Age × stressor pattern
Stronger reported responses in young rats during exhaustive loading; in old rats during restricted movementQualitative comparison in dissertation conclusions.
Baseline behavior
Lower locomotor activity and food intake described after EpithalaminReported in unstressed animals; a different endpoint from stress adaptation.
Biological measures
Leukocyte, lipid-peroxidation and blood-cell membrane changes reportedDifferent markers and conditions; no numerical treatment effect extracted.

The author reports stronger Epithalamin-associated stress-marker responses during exhaustive exercise in younger animals, and during restricted movement in older animals.

Study notes · methods, sources and limitations

Participants or model Younger and older rats; baseline, exhaustive physical loading and restricted-movement series

Design Younger and older rats; baseline, exhaustive physical loading and restricted-movement series

Important limitations

  • Exact dose and effect estimates require full methods and original outcome tables.
  • Exact dose and effect estimates require full methods and original outcome tables. Changes in behavior, lipid peroxidation and leukocyte profiles are not proof of increased athletic endurance.
  • The age and stressor matter. These results apply to the studied extract, with no demonstrated benefit in athletes.

Candidate dissertation, Saint Petersburg, 2004 · Dissertation

Original source or citation ↗

Study results and tables ↗

Animal research · 2012

Epithalamin and melatonin in rat brain during acute hypoxia

Hippocampal malondialdehyde
27.30 ± 3.28 vs 35.60 ± 3.90 vs 52.90 ± 2.36 µmol/gEpithalamin + hypoxia, melatonin + hypoxia and hypoxia alone, respectively.
Hippocampal neutral protein oxidation products
2.290 ± 0.205 vs 3.740 ± 0.274 vs 2.960 ± 0.136Same three groups. Units are mmol hydrazones/g protein.
Cortical neutral protein oxidation products
3.560 ± 0.162 vs 2.520 ± 0.367 vs 3.500 ± 0.206Same three groups. The Epithalamin result was close to hypoxia alone.

Under simulated 12,000 m hypoxia, hippocampal malondialdehyde was 27.3 µmol/g with Epithalamin, 35.6 with melatonin and 52.9 with hypoxia alone. Epithalamin reduced hippocampal protein oxidation but did not reduce cortical protein oxidation in the same pattern.

Study notes · methods, sources and limitations

Participants or model 97 young outbred male rats in the overall study. Both tables say n = 7, and the methods describe pooling tissue from two animals per suspension.

Design Six conditions included vehicle control, melatonin, Epithalamin, hypoxia alone and each drug before hypoxia. Rats of medium hypoxia resistance were used after prescreening. The chamber simulated 12,000 m until the second agonal inspiration. Cortex and hippocampus were analyzed separately.

Important limitations

  • The overall animal total cannot be allocated to arms from the table labels alone. The reported significance labels do not establish an Epithalamin-versus-melatonin comparison. These are brain tissue biomarkers after an acute challenge. The study used the pineal extract Epithalamin and did not test synthetic AEDG (Epitalon).

Bulletin of Experimental Biology and Medicine. 2012;154(1):51–53. PMID 23330089. · Publication record

Original source or citation ↗

Study results and tables ↗

Observational study · 2004

Effect of peptide preparation epithalamin on circadian rhythm of epiphyseal melatonin-producing function in elderly people

Reported changes in nighttime melatonin that differed according to baseline pineal activity.

Study notes · methods, sources and limitations

Participants or model Older adults; plasma melatonin before and after treatment

Important limitations

  • Before/after hormone measurements do not establish sleep-stage or clinical sleep benefit. The preparation is Epithalamin, not isolated AEDG.

Bull Exp Biol Med 137(4):389-391. PMID 15452611 · Indexed abstract

Original source or citation ↗

Study results and tables ↗

Randomized study in people · 2006

Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging

All-cause deaths
28% fewer in the treated group as reported
Cardiovascular mortality
Twofold lower as reported
Cardiovascular failure and respiratory disease incidence
Twofold lower as reported

The abstract describes a randomized comparison and reports favorable long-term cardiovascular and mortality outcomes with the pineal extract.

Study notes · methods, sources and limitations

Participants or model Older patients with coronary disease and accelerated cardiovascular aging; 12-year follow-up

Design Twelve-year report involving elderly coronary-disease patients, described as randomized; Epithalamin tissue extract plus basic care versus basic care.

Important limitations

  • The abstract leaves group assignment and follow-up unclear and gives no absolute event counts. Potential overlap with later follow-up reports must be checked; this is not an Epitalon trial.
  • No sample size, event counts or confidence intervals are supplied in the abstract. These are Epithalamin extract findings, not synthetic Epitalon results.

Bull Exp Biol Med 142(3):356-359. PMID 17426848 · Indexed abstract

Original source or citation ↗

Study results and tables ↗

Review of earlier studies · 2026

Epitalon and Epithalamin: A Narrative Review of Mechanistic, Preclinical, and Clinical Evidence.

Study of multiple preparations

This 2026 review separates synthetic Epitalon from the pineal extract Epithalamin. It brings together work on telomeres, circadian rhythms and cellular aging, while finding that clinical benefit and long-term safety still need stronger human studies.

Study notes · methods, sources and limitations

Participants or model Narrative review of experimental and human literature through 22 September 2026

Important limitations

  • Narrative synthesis, not a new experiment or a pooled estimate of treatment benefit. Epithalamin extract findings cannot be assigned directly to synthetic Epitalon.

International journal of molecular sciences · Indexed abstract

Original source or citation ↗

Study results and tables ↗

Research updates ↗

Compound class
Tissue-derived polypeptide complex
Research collection
Peptide bioregulation · editorial grouping
Institutions in linked studies
St. Petersburg Institute of Bioregulation and Gerontology · Chita Medical Institute
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

Clinical reports linked; see study-specific limitations

Study methods

Original reports separated from narrative reviews and patents

Independent replication

Independent replication not established by this collection

Source access

Linked abstracts, analytical papers, reviews and patents; individual scope shown below

Safety evidence

Incomplete assessment; findings do not establish safety for personal use

Open a topic for the evidence assessment.

More findings, background and history

What remains unclear

The original report and protocol would clarify group sizes, background treatment and translation. Independent replication and equivalence to current products remain uncertain.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗
PEPTIDE RESEARCH / OCT 2026

Related preparations and evidence

Evidence belongs to the preparation actually studied. A tissue extract and a synthetic peptide can belong to the same research tradition without having equivalent effects or safety.

Pineal gland: the molecular link

Epithalamin → Epitalon / AEDG

The 2017 analytical study detected AEDG in pineal polypeptide complex, after its earlier design from amino-acid composition.

Clinical evidence and limitations

Epithalamin aging cohorts and Pineamin menopause/reproductive studies concern distinct extracts. Pineamin has separate studies of sleep, semen and ovarian-reserve reports.

The extract and synthetic AEDG are distinct preparations. Unresolved cohort overlap and limited information about methods restrict interpretation of the longevity findings.

Related preparations

Some references concern related extracts, reviews or molecular identification rather than direct studies of this compound.

Explore the full bioregulator collection ↗

View this preparation in the Khavinson evidence map ↗

PATENT RESEARCH / COLLECTION UPDATED 7 NOVEMBER 2026

Patents and claimed inventions

These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.

2001 · RU2163129C1 · Pineal extracts: manufacturing and composition patentPlatform context · Reported decreases of 15%, 22% and 29.4% from baseline

Reported findings

The disclosed extract was associated with lower reported glucose measures over 12 weeks, without a verified product-specific Epithalamin match.

Fasting glycemia
Reported decreases of 15%, 22% and 29.4% from baselineWeeks 2, 4 and 12Treated group; baseline glucose values and modern allocation details not extracted
Postprandial glycemia
Reported decreases of 18.2%, 28% and 41%Weeks 2, 4 and 12Not absolute glucose concentrations
All reported results, comparisons and limitations →

Platform context. The patent describes animal-pineal polypeptide complexes and proposed antioxidant or geroprotective uses, providing context for pineal-extract research.

A product-specific match to commercial Epithalamin was not established. This tissue-complex patent is not the defined AEDG Epitalon molecular patent, nor proof of human longevity.

Publication
RU2163129C1 ↗ · 2001-02-20
Earliest priority / filing
2000-06-29 / 2000-06-29
Original applicant / assignee
Общество с ограниченной ответственностью "Клиника Института биорегуляции и геронтологии"
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
20236906 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Method of preparing animal-origin complex of biologically-active polypeptides exhibiting antioxidant and geroprotection activities, pharmacological agent, and method for utilization thereof

Inventors: В.Х. Хавинсон; В.Г. Морозов; В.И. Семенова; О.В. Чайка; Г.А. Рыжак.

RU2163129C1

Original patent PDF ↗

Read source review →

Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →

03 / SOURCE RECORDS

Findings by study

Explore related research ↗

Comparison in people · 2011

Epithalamin and 15-year follow-up in older adults with coronary disease

At 15 years, 26/39 patients in the Epithalamin group and 16/40 in the standard-care group were alive. This small historical comparison followed patients with coronary disease.

Alive at 15 years · 26/39 (66.7%) vs 16/40 (40.0%) · Epithalamin plus standard care versus standard care.

Study notes and original source
2011Human comparative studyFull text available

Epithalamin and 15-year follow-up in older adults with coronary disease

O. V. Korkushko, V. Kh. Khavinson, V. B. Shatilo, I. A. Antoniuk-Shcheglova · Bulletin of Experimental Biology and Medicine. 2011;151(3):366–369. PMID 22451889.

At 15 years, 26/39 patients in the Epithalamin group and 16/40 in the standard-care group were alive. This small historical comparison followed patients with coronary disease.

Results and tables

Reported findings and study design

Reported randomized comparative follow-up from the Kyiv gerontology program with survival curves and cardiovascular outcomes.

Population or model 79 older patients with coronary disease. Thirty-nine received adjunctive Epithalamin and 40 received standard care alone.

Dose, route and schedule

10 mg in 2 mL saline intramuscularly every third morning, five injections per course (50 mg per course). Six courses at six-month intervals over the first three years, with basic therapy. The 15-year result is follow-up after that treatment period.

Protocol source ↗ · Original English paper and indexed Russian-program publications. Compared with an earlier 12-year report and a Palermo conference citation.

Results · Original English paper and indexed Russian-program publications. Compared with an earlier 12-year report and a Palermo conference citation.
MeasureResultComparison, timing and statistics
Alive at 15 years26/39 (66.7%) vs 16/40 (40.0%)Epithalamin plus standard care versus standard care.
Deaths attributed to myocardial infarction or stroke6/13 deaths vs 20/24 deathsCause-of-death counts among participants who died.

Source for these results ↗ · Reviewed 2026-11-14

Population / setting
79 older patients with coronary disease. Thirty-nine received adjunctive Epithalamin and 40 received standard care alone.
Source reviewed
Original English paper and indexed Russian-program publications. Compared with an earlier 12-year report and a Palermo conference citation.
Study limitations
  • Small historical comparison, with limited reporting about masking and subsequent treatment. The associated 12-year paper may share the same participants.
  • Epithalamin is a pineal extract. The study did not administer synthetic Epitalon.

Reviewed 2026-11-14.

Read the source ↗

Animal research · 2018

Thymogen and four peptide preparations in hypoxia, heat and cold

The 2014 and 2018 course-hypoxia tables repeat the same experiment.

Study notes and original source
2018Animal / experimentalRussian-language source

Thymogen and four peptide preparations in hypoxia, heat and cold

· Biomeditsina 2018(2):4–14, Tables 1–3; paired with 2014 Volume III Table 11

Format: Original 2018 methods and Tables 1–3 compared with Volume III Chapter 7, pp. 174–177. · Reviewed: Reported methods, results and evidence limitations

E. B. Shustov, M. T. Gasanov, G. D. Kapanadze, Yu. V. Fokin, V. S. Novikov, E. L. Matveenko, Kh. Kh. Semenov · Biomeditsina 2018(2):4–14, Tables 1–3; paired with 2014 Volume III Table 11

In the three-day rat comparison, Thymogen at 0.1 mg/kg gave 28.6±11.8 min versus 2.2±0.1 with saline. All 16 arms and their reported values match the 2014 monograph. Thymogen had no significant benefit on the air-cooling endpoint.

Results and tables

Reported findings and study design

In the three-day rat comparison, Thymogen at 0.1 mg/kg gave 28.6±11.8 min versus 2.2±0.1 with saline. All 16 arms and their reported values match the 2014 monograph. Thymogen had no significant benefit on the air-cooling endpoint.

The single-dose mouse screen used 10,000 m, 8–10 per dose in the 2018 report (6–10 in the 2014 book). Table 1 instead reports a three-day rat series tested at 11,500 m the next day. Arm sizes for the repeated-dose table are not stated in the audited passage.

Population or model Outbred male mice in the single-dose hypoxia screen; male rats (180–210 g) in the repeated-dose hypoxia table. Separate temperature experiments.

Dose, route and schedule

Historical animal protocol. Intraperitoneal dosing daily for three days for the course hypoxia series. Thymogen 0.001, 0.01 or 0.1 mg/kg, with distinct dose ranges for the other preparations.

Protocol source ↗ · Original 2018 methods and Tables 1–3 compared with Volume III Chapter 7, pp. 174–177.

Results · Original 2018 methods and Tables 1–3 compared with Volume III Chapter 7, pp. 174–177.
MeasureResultComparison, timing and statistics
Thymogen · course hypoxia10.6±3.2, 20.1±11.1 and 28.6±11.8 minAt 0.001, 0.01 and 0.1 mg/kg respectively. Saline 2.2±0.1 min. · p<0.05, p<0.01 and p<0.01 versus saline as marked.
Thymalin · course hypoxia7.1±2.6 min at 0.1 mg/kg versus 2.2±0.1 min saline0.5 mg/kg arm was unmarked for significance. · p<0.05 for 0.1 mg/kg
Cortexin · course hypoxia and heat5.2±3.2 min at 1 mg/kg in hypoxia; 88.6±2.4 vs 96.5±5.2 min at 5 mg/kg in heatSeparate stress experiments and different doses. The heat endpoint shortened. · Both selected contrasts p<0.05 as marked
Prostatilen · course hypoxia7.0±5.6 min at 0.1 mg/kg versus 2.2±0.1 min salineAt 0.5 mg/kg: 4.2±0.7 min and a 66% increase in resistant animals as printed. · 0.1 mg/kg time p<0.01 as marked
Epithalamin · course hypoxia and cold7.4±4.5 min at 10 mg/kg in hypoxia; 194±22 vs 168±12 min at 0.5 mg/kg in air coolingSeparate dose and stress protocols. 1 mg/kg hypoxia arm was unmarked. · Both selected contrasts p<0.05 as marked
Thymogen · air cooling185±25 vs 168±12 min to rectal temperature of 35°C0.05 mg/kg versus control. No significant contrast marked.
Publication overlap2014 Table 11 and 2018 Table 1 repeat the same valuesCounts as one reported experiment. Both publications also describe a distinct acute mouse screen.
Matched course-hypoxia data · 2014 Table 11 and 2018 Table 1
Matched course-hypoxia data · 2014 Table 11 and 2018 Table 1
ArmDose (mg/kg unless noted)Time (min)Reported change (%)Resistant-animal share increase (%)
Saline1.0 as printed2.2±0.100
Thymalin0.17.1±2.6*23838
Thymalin0.53.7±1.07616
Thymalin1.04.4±2.2*11016
Cortexin0.13.9±1.4865
Cortexin0.53.8±0.4*8116
Cortexin1.05.2±3.2*1485
Prostatilen0.17.0±5.6**2330
Prostatilen0.54.2±0.7*10066*
Prostatilen1.02.4±1.01416
Epithalamin0.12.7±0.62215
Epithalamin1.01.8±0.500
Epithalamin10.07.4±4.5*23633
Thymogen0.00110.6±3.2*40548*
Thymogen0.0120.1±11.1**85760*
Thymogen0.128.6±11.8**126280**

M±m. * p<0.05, ** p<0.01 versus saline. Percentage column transcribed as printed and may differ from calculations using rounded means. The book’s adjacent mouse protocol describes the acute screen.

The papers distinguish the single-dose mouse screen from the three-day rat protocol. The matching table adds no independent animals or human participants.

Source for these results ↗ · Reviewed 2026-11-09

Population / setting
Outbred male mice in the single-dose hypoxia screen; male rats (180–210 g) in the repeated-dose hypoxia table. Separate temperature experiments.
Source reviewed
Original 2018 methods and Tables 1–3 compared with Volume III Chapter 7, pp. 174–177.
Study limitations
  • The 2018 rat course results and 2014 book table belong to one evidence family. The book omits an explicit course-series species and altitude in the adjacent paragraph.
  • Short survival in an extreme animal model is separate from human endurance or safety.

Reviewed 2026-11-09.

Read the source ↗

Comparison in people · 2014

Four intranasal peptide arms at simulated 4,500 m

Table 12 compares four small peptide arms with saline at 4,500 m.

Study notes and original source
2014Human comparative studyRussian-language source

Four intranasal peptide arms at simulated 4,500 m

· Essays on Sports Pharmacology, Vol. III, Vectors of Pharmacoregulation, Chapter 7, pp. 177–180, Table 12

Format: Original publication and selected methods and results checked · Reviewed: Reported methods, results and evidence limitations

N. N. Karkishchenko, V. V. Uyba, V. N. Karkishchenko, E. B. Shustov, K. V. Kotenko, S. L. Lyublinskiy · Essays on Sports Pharmacology, Vol. III, Vectors of Pharmacoregulation, Chapter 7, pp. 177–180, Table 12

Thymogen was associated with lower lactate during the chamber protocol. Cortexin showed longer complex reaction latency alongside other physiological changes. The endpoints were heterogeneous.

Results and tables

Reported findings and study design

Thymogen was associated with lower lactate during the chamber protocol. Cortexin showed longer complex reaction latency alongside other physiological changes. The endpoints were heterogeneous.

Author-described random assignment. Exposure for 60–80 min at simulated 4,500 m with postural testing, a three-minute 100 W cycling load, motor tasks and blood measurements.

Population or model Men aged 20–25 with asthenic or immune-status features. Four active arms of 6–8 each and 11 saline controls.

Dose, route and schedule

Single intranasal administration one hour before ascent: Thymogen 1 µg, Cortexin 10 mg, Epithalamin 10 mg or Prostatilen 5 mg. The control received equivalent-volume saline.

Protocol source ↗ · Original publication and selected methods and results checked

Results · Original publication and selected methods and results checked
MeasureResultComparison, timing and statistics
Thymogen · blood lactate1.81±0.21 vs 2.98±0.46Source Table 12 units not specified on the row. · p<0.05 versus saline
Cortexin · complex visuomotor reaction latency423±12 vs 381±9 msSlower response, even with some favorable markers. · p<0.01 versus saline
Epithalamin · number of complaints0.33±0.13 vs 1.4±0.5Authors marked a trend. · p<0.1 versus saline
Prostatilen · number of complaints0.2±0.2 vs 1.4±0.5Small short-term comparison. · p<0.05 versus saline

The 4,500 m protocol differs from Cheprasov’s 5,000 m comparison. Participant independence has not been established and this series adds no people to the historical tally.

Source for these results ↗ · Reviewed 2026-11-09

Population / setting
Men aged 20–25 with asthenic or immune-status features. Four active arms of 6–8 each and 11 saline controls.
Source reviewed
Original publication and selected methods and results checked
Study limitations
  • Small arms, numerous endpoints and several comparisons reported at p<0.1. Exact allocation counts and overlap with the Medilab lineage remain unresolved.

Reviewed 2026-11-09.

Read the source ↗

Comparison in people · 1997

Cheprasov’s Medilab peptide comparisons in aerospace stress

The three test series covered hypoxia, motion tolerance and 24 hours of work. The abstract reports favorable task results for selected peptides and gives a tiny separate postflight Thymogen comparison.

Study notes and original source
1997Human comparative studyRussian-language source

Cheprasov’s Medilab peptide comparisons in aerospace stress

· Kirov Military Medical Academy doctoral dissertation author abstract, Table 1 and methods

Format: Author’s abstract transcription. Full dissertation and underlying records unavailable. · Reviewed: Reported methods, results and evidence limitations

V. V. Cheprasov · Kirov Military Medical Academy doctoral dissertation author abstract, Table 1 and methods

The three test series covered hypoxia, motion tolerance and 24 hours of work. The abstract reports favorable task results for selected peptides and gives a tiny separate postflight Thymogen comparison.

Results and tables

Reported findings and study design

The three test series covered hypoxia, motion tolerance and 24 hours of work. The abstract reports favorable task results for selected peptides and gives a tiny separate postflight Thymogen comparison.

Hypobaric test: three arms of 10 at 5,000 m for 60 min. Motion: seven arms of 10 in a Coriolis test. Work: four arms of four at 50% of individually tolerated load. Postflight: four mission pairs, one participant per pair given Thymogen.

Population or model 116 men across three stress comparisons (30, 70 and 16), plus an eight-cosmonaut comparison within the reported dissertation program of 328.

Dose, route and schedule

Hypoxia: intranasal Cortexin or Thymalin, 20 mg per course over two days, or placebo. Motion: single intranasal 5 mg Thymalin, Cortexin, Prostatilen or Epithalamin, or 50 µg Thymogen, with oral scopolamine 0.1 mg and placebo controls. Work: nasal Thymogen 100 µg or Cortexin 10 mg before work and after 6 and 12 h, or oral sydnocarb plus Bemitil, or saline. Postflight: intranasal Thymogen 100 µg/day for seven days.

Protocol source ↗ · Author’s abstract transcription. Full dissertation and underlying records unavailable.

Results · Author’s abstract transcription. Full dissertation and underlying records unavailable.
MeasureResultComparison, timing and statistics
Hypobaric comparisonThymalin: 15–20% higher work measures; Cortexin: 10–15% improvement in selected operator measuresAbstract narrative; full arm-level estimates unavailable.
Coriolis motion toleranceCortexin +89%, Thymogen +73%, Epithalamin +68%Reported tolerance-time improvement relative to control, ten per arm.
Sustained workAuthor reported recovery of selected Thymogen-group measures to baseline by three hoursFour per arm. Cortexin and oral Bemitil plus sydnocarb were separate comparators.
Postflight respiratory infections1 of 4 in Thymogen arm versus 4 of 4 salineReported during the following year, a descriptive count from four pairs.
Program headcount328 stated; stage rows add to 338The 116 and 8 are subseries, with no additional headcount contributed to the historical tally.

The aerospace findings concern separate stress and recovery tasks, with no reliable pooled treatment effect.

Source for these results ↗ · Reviewed 2026-11-09

Population / setting
116 men across three stress comparisons (30, 70 and 16), plus an eight-cosmonaut comparison within the reported dissertation program of 328.
Source reviewed
Author’s abstract transcription. Full dissertation and underlying records unavailable.
Study limitations
  • Small comparisons, incomplete outcome reporting and unclear separation from related Medilab publications.
  • The 47 modeling experts were outside the participant table.

Reviewed 2026-11-09.

Read the source ↗

Animal research · 2006

Age and baseline anxiety in Lysenko’s peptide stress models

The author reported that the direction of peptide-associated changes depended on age and baseline anxiety. Some shifts were unfavorable.

Study notes and original source
2006Animal / experimentalRussian-language source

Age and baseline anxiety in Lysenko’s peptide stress models

· Doctoral dissertation, 244 pp., introduction and conclusions

Format: Author’s abstract transcription. Full dissertation and underlying records unavailable. · Reviewed: Reported methods, results and evidence limitations

A. V. Lysenko · Doctoral dissertation, 244 pp., introduction and conclusions

The author reported that the direction of peptide-associated changes depended on age and baseline anxiety. Some shifts were unfavorable.

Results and tables

Reported findings and study design

The author reported that the direction of peptide-associated changes depended on age and baseline anxiety. Some shifts were unfavorable.

Hypokinesia, hypoxia and exertion models, with behavioral, immune and oxidative endpoints. Twenty-four-hour hypokinesia was one stress protocol.

Population or model Rats grouped by age and baseline anxiety; series-specific denominators remain unverified.

Results · Author’s abstract transcription. Full dissertation and underlying records unavailable.
MeasureResultComparison, timing and statistics
High-anxiety young ratsVilon and GVS-111 were highlighted in the author’s conclusionsOriginal group-level numerical estimates and doses still need retrieval.
Stress-response directionFavorable and unfavorable responses describedThe author discusses this for GVS-111 and an experimental preparation called NKT. NKT identity remains unresolved.

A mechanistic program on stress response. The dissertation-level conclusion does not isolate all preparation-specific effects.

Source for these results ↗ · Reviewed 2026-11-09

Population / setting
Rats grouped by age and baseline anxiety; series-specific denominators remain unverified.
Source reviewed
Author’s abstract transcription. Full dissertation and underlying records unavailable.
Study limitations
  • Potential overlap with narrower author-network dissertations, including Morgul and Rudenko. Outcomes cannot be pooled or assigned to humans.

Reviewed 2026-11-09.

Read the source ↗

Animal research · 2004

Epithalamin under exercise and restricted movement in younger and older rats

The author reports stronger Epithalamin-associated stress-marker responses during exhaustive exercise in younger animals, and during restricted movement in older animals.

Study notes and original source
2004Animal / experimentalRussian-language source

Epithalamin under exercise and restricted movement in younger and older rats

Epithalamin pineal extract; distinct from Epitalon, Pinealon and Pineamin. · Dissertation

Format: Accessible dissertation or author-abstract transcription; full scan and original tables not recovered · Reviewed: Reported methods, results and evidence limitations

T. N. Rudenko · Candidate dissertation, Saint Petersburg, 2004

The author reports stronger Epithalamin-associated stress-marker responses during exhaustive exercise in younger animals, and during restricted movement in older animals.

Results and tables

Reported findings and study design

The author reports stronger Epithalamin-associated stress-marker responses during exhaustive exercise in younger animals, and during restricted movement in older animals.

Younger and older rats; baseline, exhaustive physical loading and restricted-movement series

Population or model Younger and older rats; baseline, exhaustive physical loading and restricted-movement series

Results · Accessible dissertation or author-abstract transcription; full scan and original tables not recovered
MeasureResultComparison, timing and statistics
Age × stressor patternStronger reported responses in young rats during exhaustive loading; in old rats during restricted movementQualitative comparison in dissertation conclusions.
Baseline behaviorLower locomotor activity and food intake described after EpithalaminReported in unstressed animals; a different endpoint from stress adaptation.
Biological measuresLeukocyte, lipid-peroxidation and blood-cell membrane changes reportedDifferent markers and conditions; no numerical treatment effect extracted.

The age and stressor matter. These results apply to the studied extract, with no demonstrated benefit in athletes.

Source for these results ↗ · Reviewed 2026-11-08

Population / setting
Younger and older rats; baseline, exhaustive physical loading and restricted-movement series
Source reviewed
Accessible dissertation or author-abstract transcription; full scan and original tables not recovered
Study limitations
  • Exact dose and effect estimates require full methods and original outcome tables.
  • Changes in behavior, lipid peroxidation and leukocyte profiles are not proof of increased athletic endurance.

Reviewed 2026-11-08.

Read the source ↗

Animal research · 2012

Melatonin and pineal gland peptides are able to correct the impairment of reproductive cycles in rats

Epithalamin reportedly restored hypothalamic norepinephrine rhythms, while Epitalon had a stronger dopamine-rhythm effect in another hypothalamic region. The experiment used 1,2-dimethylhydrazine, not a pregnancy model or a methionine-only intervention.

Study notes and original source
2012Animal / experimentalEnglish abstract

Melatonin and pineal gland peptides are able to correct the impairment of reproductive cycles in rats

Epitalon (Ala-Glu-Asp-Gly), Epithalamin pineal extract and melatonin in separate comparisons · Original journal publication

Format: Publication record and available text · Reviewed: Indexed original abstract; full methods and outcome tables not recovered

Arutjunyan A, Kozina L, Milyutina Y, Korenevsky A, Stepanov M, Arutyunov V · Current aging science. 2012;5(3):178-85. PMID 23237594

Epithalamin reportedly restored hypothalamic norepinephrine rhythms, while Epitalon had a stronger dopamine-rhythm effect in another hypothalamic region. The experiment used 1,2-dimethylhydrazine, not a pregnancy model or a methionine-only intervention.

Results and tables

Reported findings and study design

Findings described in words

Epithalamin reportedly restored hypothalamic norepinephrine rhythms, while Epitalon had a stronger dopamine-rhythm effect in another hypothalamic region. The experiment used 1,2-dimethylhydrazine, not a pregnancy model or a methionine-only intervention.

Single 1,2-dimethylhydrazine exposure in female rats; region- and circadian-time-specific catecholamine measurements after melatonin or pineal-peptide interventions.

Population or model Nonpregnant female rats in a xenobiotic-induced reproductive-aging model; n absent from abstract

Results · Indexed original abstract; full methods and outcome tables not recovered
MeasureResultComparison, timing and statistics
EpithalaminRecovery of norepinephrine diurnal dynamics in medial preoptic areaNorepinephrine decreased between 09:30 and 11:00 circadian time
EpitalonDopamine remained low at 05:00 and increased by 11:00 circadian timeMedian eminence/arcuate region; no numerical concentrations supplied
Pregnancy and fertility outcomesNo pregnant cohort, congenital-anomaly rate or verified live-birth benefit in the abstract

Reproductive-cycle neurochemistry is not pregnancy-safety evidence or proof of improved human fertility. Epitalon is a defined tetrapeptide; Epithalamin is a bovine pineal peptide extract. Their findings are not interchangeable. Doses, n, allocation, quantitative effect sizes and adverse-event surveillance unavailable in the abstract.

Source for these results ↗ · Reviewed 2026-11-08

Population / setting
Nonpregnant female rats in a xenobiotic-induced reproductive-aging model; n absent from abstract
Source reviewed
Indexed original abstract; full methods and outcome tables not recovered
Study limitations
  • Reproductive-cycle neurochemistry is not pregnancy-safety evidence or proof of improved human fertility.
  • Epitalon is a defined tetrapeptide; Epithalamin is a bovine pineal peptide extract. Their findings are not interchangeable.
  • Doses, n, allocation, quantitative effect sizes and adverse-event surveillance unavailable in the abstract.

Reviewed 2026-11-08.

Read the source ↗

Comparison in people · 2008

Thymalin, Epithalamin and Vilon after complicated appendicitis

In this small comparison, mean stay was 6.2 days shorter with Epithalamin plus standard care. The standard-care group averaged 24.2 days.

Study notes and original source
2008Human comparative studyFull text available

Thymalin, Epithalamin and Vilon after complicated appendicitis

Author affiliations · Chita Medical Institute

· Original clinical journal article

B. I. Kuznik, Kh. R. Abdulaev, Yu. A. Vitkovsky, I. D. Likhanov, M. N. Tsybikov, N. N. Tsybikov · Medical Immunology. 2008;10(4–5):455–462.

Mean hospital stay was 24.2 days with standard care and 18.0–19.0 days in the four adjunct groups. TNF-α fell most in the Vilon cytokine subset. IL-8 increased in every measured group.

Results and tables

Reported findings and study design

Comparison of standard care and peptide adjuncts after postoperative wound infection. The paper measured serum cytokines by immunoassay and compared immune markers before and after treatment.

Population or model 84 adults aged 18–42: 12 with uncomplicated appendicitis and 72 with postoperative wound infection. Of the 72, 62 received a peptide adjunct. Thirty healthy volunteers were a laboratory reference group.

Dose, route and schedule

Standard care included abscess drainage, antibiotics and symptomatic treatment. The reported adjuncts were intramuscular Thymalin or Epithalamin at 10 mg per injection for 10 days, or Vilon at 10 µg per injection for five or ten days.

Protocol source ↗ · Original article, pp. 455–456

Results · Original 2008 journal PDF, pp. 455–461, including Table 3
MeasureResultComparison, timing and statistics
Mean hospitalization24.2 days with standard care versus 18.0–19.0 days with peptide adjunctsUnadjusted group means from five small, unequal groups.
TNF-α in the Vilon cytokine subset447 ± 20 to 115 ± 9 pg/mL (n = 25)Within-group p < 0.001 in Table 3
IL-8Rose in all four cytokine groups, including standard care.
Wound closure and safetyThe authors described primary wound healing. No arm-level wound-healing rate or systematic adverse-event table was recovered.
Reported hospital stay by treatment group
Reported hospital stay by treatment group
GroupPatientsMean days ± reported uncertaintyDifference from standard care
Standard care1024.2 ± 0.6Reference
Thymalin1019.0 ± 0.75.2 days shorter
Epithalamin1218.0 ± 0.66.2 days shorter
Vilon, five days3018.8 ± 0.65.4 days shorter
Vilon, ten days1019.0 ± 0.55.2 days shorter

Differences are calculated from published means. The paper does not clearly identify the contrast for the p-values printed alongside these means.

Table 3: serum cytokines before → after treatment
Table 3: serum cytokines before → after treatment
Cytokine (pg/mL)Healthy referenceStandard care (n = 10)Thymalin (n = 10)Epithalamin (n = 12)Vilon (n = 25)
TNF-α13 ± 4432 ± 32 → 389 ± 25396 ± 28 → 186 ± 21486 ± 28 → 205 ± 19447 ± 20 → 115 ± 9
IL-818 ± 5126 ± 18 → 678 ± 31146 ± 20 → 383 ± 24159 ± 19 → 453 ± 28175 ± 16 → 418 ± 25
IL-1α12 ± 3105 ± 28 → 88 ± 15123 ± 21 → 58 ± 12135 ± 20 → 87 ± 14131 ± 11 → 52 ± 6
IL-1β8 ± 2368 ± 24 → 142 ± 19326 ± 23 → 245 ± 24310 ± 22 → 318 ± 25Not reported

Mean ± standard error as labeled in the PDF. TNF-α within-group p > 0.05 with standard care and p < 0.001 in each adjunct group. Vilon’s cytokine subset is distinct from its 40-person hospital-stay comparison. Values follow the original PDF text where digital transcriptions disagree.

Vilon showed the largest within-group TNF-α decrease. Hospitalization means were close among the four adjunct groups. Neither outcome establishes a comparative treatment effect.

Source for these results ↗ · Reviewed 2026-11-10

Population / setting
84 adults aged 18–42: 12 with uncomplicated appendicitis and 72 with postoperative wound infection. Of the 72, 62 received a peptide adjunct. Thirty healthy volunteers were a laboratory reference group.
Source reviewed
Original journal PDF text, methods and Tables 1 and 3 checked. The 321st District Military Clinical Hospital in Chita was an author affiliation.
Study limitations
  • Small, unequal groups and unclear treatment assignment leave confounding unresolved. The article does not establish that Vilon was superior or equivalent to the other adjuncts.
  • The Vilon hospital groups totaled 40. The cytokine table included 25, with no breakdown by treatment duration.
  • The hospitalization paragraph prints p < 0.01 after each mean without clearly specifying a contrast. No systematic adverse-event table or quantified wound-healing rates were recovered.

Reviewed 2026-11-10.

Read the source ↗

Animal research · 2012

Epithalamin and melatonin in rat brain during acute hypoxia

Under simulated 12,000 m hypoxia, hippocampal malondialdehyde was 27.3 µmol/g with Epithalamin, 35.6 with melatonin and 52.9 with hypoxia alone. Epithalamin reduced hippocampal protein oxidation but did not reduce cortical protein oxidation in the same pattern.

Hippocampal malondialdehyde · 27.30 ± 3.28 vs 35.60 ± 3.90 vs 52.90 ± 2.36 µmol/g · Epithalamin + hypoxia, melatonin + hypoxia and hypoxia alone, respectively.

Study notes and original source
2012Animal / experimentalFull text available

Epithalamin and melatonin in rat brain during acute hypoxia

I. I. Zamorskii, I. Yu. Sopova, V. Kh. Khavinson · Bulletin of Experimental Biology and Medicine. 2012;154(1):51–53. PMID 23330089.

Under simulated 12,000 m hypoxia, hippocampal malondialdehyde was 27.3 µmol/g with Epithalamin, 35.6 with melatonin and 52.9 with hypoxia alone. Epithalamin reduced hippocampal protein oxidation but did not reduce cortical protein oxidation in the same pattern.

Results and tables

Reported findings and study design

Reported findings

Six conditions included vehicle control, melatonin, Epithalamin, hypoxia alone and each drug before hypoxia. Rats of medium hypoxia resistance were used after prescreening. The chamber simulated 12,000 m until the second agonal inspiration. Cortex and hippocampus were analyzed separately.

Population or model 97 young outbred male rats in the overall study. Both tables say n = 7, and the methods describe pooling tissue from two animals per suspension.

Dose, route and schedule

Epithalamin 2.5 mg/kg or melatonin 1 mg/kg was injected intraperitoneally 30 minutes before simulated altitude exposure. Separate arms received the preparations in normoxia. Tissue was collected 30 minutes after acute hypoxia.

Protocol source ↗ · Original article Methods

Results · Complete translated article, Tables 1 and 2
MeasureResultComparison, timing and statistics
Hippocampal malondialdehyde27.30 ± 3.28 vs 35.60 ± 3.90 vs 52.90 ± 2.36 µmol/gEpithalamin + hypoxia, melatonin + hypoxia and hypoxia alone, respectively.
Hippocampal neutral protein oxidation products2.290 ± 0.205 vs 3.740 ± 0.274 vs 2.960 ± 0.136Same three groups. Units are mmol hydrazones/g protein.
Cortical neutral protein oxidation products3.560 ± 0.162 vs 2.520 ± 0.367 vs 3.500 ± 0.206Same three groups. The Epithalamin result was close to hypoxia alone.
Malondialdehyde by region, Table 2 (µmol/g tissue)
Malondialdehyde by region, Table 2 (µmol/g tissue)
ExposureCortexHippocampus
Control46.50 ± 1.6145.50 ± 1.35
Hypoxia54.10 ± 1.8352.90 ± 2.36
Melatonin43.10 ± 1.4636.00 ± 1.29
Epithalamin38.60 ± 1.2934.70 ± 4.72
Melatonin + hypoxia38.80 ± 1.3435.60 ± 3.90
Epithalamin + hypoxia38.50 ± 1.3127.30 ± 3.28

Mean ± error as printed (M ± m, table n = 7). These values are tissue markers rather than measures of neuronal survival.

Source for these results ↗ · Reviewed 2026-11-11

Population / setting
97 young outbred male rats in the overall study. Both tables say n = 7, and the methods describe pooling tissue from two animals per suspension.
Source reviewed
Complete translated article, methods and both printed tables visually checked.
Study limitations
  • The overall animal total cannot be allocated to arms from the table labels alone.
  • The reported significance labels do not establish an Epithalamin-versus-melatonin comparison.
  • These are brain tissue biomarkers after an acute challenge. The study used the pineal extract Epithalamin and did not test synthetic AEDG (Epitalon).

Reviewed 2026-11-11.

Read the source ↗

Experiment described in a patent · 2001

Pineal extracts: manufacturing and composition patent — RU2163129C1

The disclosed extract was associated with lower reported glucose measures over 12 weeks, without a verified product-specific Epithalamin match.

Fasting glycemia · Reported decreases of 15%, 22% and 29.4% from baseline · Treated group; baseline glucose values and modern allocation details not extracted · Weeks 2, 4 and 12

Study notes and original source
2001Patent / reported experimentsFull text available

Pineal extracts: manufacturing and composition patent — RU2163129C1

Patent-defined substance or composition · Patent publication

Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

В.Х. Хавинсон, В.Г. Морозов, В.И. Семенова, О.В. Чайка, Г.А. Рыжак · RU2163129C1 · patent family 20236906

The disclosed extract was associated with lower reported glucose measures over 12 weeks, without a verified product-specific Epithalamin match.

Results and tables

Reported patent results

Reported findings

The disclosed extract was associated with lower reported glucose measures over 12 weeks, without a verified product-specific Epithalamin match.

Pineal-extract patent includes a type-2-diabetes clinical comparison: 33 treated patients and a 24-person control group.

Population or model Pineal-extract patent includes a type-2-diabetes clinical comparison: 33 treated patients and a 24-person control group.

Results · 33-patient diabetes example, 24-person control narrative and Table 6 discussion.
MeasureResultComparison, timing and statistics
Fasting glycemiaReported decreases of 15%, 22% and 29.4% from baselineTreated group; baseline glucose values and modern allocation details not extracted · Weeks 2, 4 and 12
Postprandial glycemiaReported decreases of 18.2%, 28% and 41%Not absolute glucose concentrations · Weeks 2, 4 and 12
Control and HbA1cNo significant control-group glycemic change; treated HbA1c described as decreased without an extracted numerical valueNo invented HbA1c effect size

Concurrent diabetes care, incompletely specified allocation and patent reporting prevent a causal estimate. The extract is not synthetic AEDG; commercial Epithalamin equivalence and longevity benefit are unproven.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Pineal-extract patent includes a type-2-diabetes clinical comparison: 33 treated patients and a 24-person control group.
Source reviewed
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
  • A product-specific match to commercial Epithalamin was not established. This tissue-complex patent is not the defined AEDG Epitalon molecular patent, nor proof of human longevity.
  • Concurrent diabetes care, incompletely specified allocation and patent reporting prevent a causal estimate. The extract is not synthetic AEDG; commercial Epithalamin equivalence and longevity benefit are unproven.
  • Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
  • Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Reviewed 2026-11-06.

Read the source ↗

Review of earlier studies · 2026

Epitalon and Epithalamin: A Narrative Review of Mechanistic, Preclinical, and Clinical Evidence.

This 2026 review separates synthetic Epitalon from the pineal extract Epithalamin. It brings together work on telomeres, circadian rhythms and cellular aging, while finding that clinical benefit and long-term safety still need stronger human studies.

Study notes and original source
2026ReviewEnglish abstract

Epitalon and Epithalamin: A Narrative Review of Mechanistic, Preclinical, and Clinical Evidence.

Jain A, Gallacher DM, Issa MA, Deer TR, Yong RJ, Diwan S, Lee W, Sayed D, Amirdelfan K, Robinson CL · International journal of molecular sciences

This 2026 review separates synthetic Epitalon from the pineal extract Epithalamin. It brings together work on telomeres, circadian rhythms and cellular aging, while finding that clinical benefit and long-term safety still need stronger human studies.

Population / setting
Narrative review of experimental and human literature through 22 September 2026
Source reviewed
Publication metadata and indexed abstract checked through Europe PMC on 28 October 2026; full text not appraised.
Study limitations
  • Narrative synthesis, not a new experiment or a pooled estimate of treatment benefit.
  • Epithalamin extract findings cannot be assigned directly to synthetic Epitalon.

Reviewed 2026-10-28.

Read the source ↗

Research record · 2003

Эффективность применения пептидных биорегуляторов у лиц разного возраста в условиях Крайнего Севера — Effectiveness of peptide bioregulators in people of different ages under Far North conditions

The dissertation trail links examinations of Gazprom employees and family members to the program approved in February 2000. Indexed recommendations name sequential Thymalin, Epithalamin and Cortexin for a disease-specific setting; they do not establish a universal occupational regimen.

Study notes and original source
2003Study design unresolvedBibliographic record

Эффективность применения пептидных биорегуляторов у лиц разного возраста в условиях Крайнего Севера — Effectiveness of peptide bioregulators in people of different ages under Far North conditions

Thymalin, Epithalamin and Cortexin tissue-derived preparations · Dissertation record and indexed excerpts

Vladimir Alekseevich Cherkashin · Candidate of Medical Sciences dissertation, St. Petersburg, 2003; 203 pages

The dissertation trail links examinations of Gazprom employees and family members to the program approved in February 2000. Indexed recommendations name sequential Thymalin, Epithalamin and Cortexin for a disease-specific setting; they do not establish a universal occupational regimen.

Population / setting
Far North clinical research associated with Gazprom employees and families; exact cohort allocation unresolved
Source reviewed
Available sources include bibliographic metadata and dissertation excerpts. The complete thesis was unavailable for review.
Study limitations
  • Full 203-page dissertation has not been obtained.
  • Search-indexed excerpts are not a substitute for original methods and tables.
  • Named sequential therapy for dyscirculatory encephalopathy does not identify treatment for every Gazprom employee.
  • Overlap with the broader program and other clinical cohorts remains unresolved.

Reviewed 2026-10-02.

Read the source ↗

Review of earlier studies · 2013

Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results

Summarizes clinical work on seven named peptide preparations. Useful for tracing original Russian reports and distinguishing tissue extracts from short peptides.

Study notes and original source
2013ReviewEnglish abstract

Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results

Khavinson VKh, Kuznik BI, Ryzhak GA · Adv Gerontol 26(1):20-37. PMID 24003726

Summarizes clinical work on seven named peptide preparations. Useful for tracing original Russian reports and distinguishing tissue extracts from short peptides.

Population / setting
Originating group’s clinical and gerontology literature
Source reviewed
Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Study limitations
  • Review by investigators in the originating program; not independent replication.
  • Clinical findings must be traced to the exact preparation and original study.

Reviewed 2026-09-29.

Read the source ↗

Laboratory analysis · 2017

Identification of Peptide AEDG in the Polypeptide Complex of the Pineal Gland

Mass spectrometry/HPLC and selective reaction monitoring identified AEDG in the pineal complex. This supplies a molecular link to the synthetic tetrapeptide.

Study notes and original source
2017Analytical / composition studyEnglish abstract

Identification of Peptide AEDG in the Polypeptide Complex of the Pineal Gland

Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology

Khavinson VK, Kopylov AT, Vaskovsky BV, Ryzhak GA, Lin'kova NS · Bull Exp Biol Med 164(1):41-43. PMID 29124531

Mass spectrometry/HPLC and selective reaction monitoring identified AEDG in the pineal complex. This supplies a molecular link to the synthetic tetrapeptide.

Results and tables

Reported findings and study design

HPLC/mass-spectrometry analysis of pineal polypeptide complex; AEDG identified among tetrapeptides.

Population or model Pineal polypeptide-complex composition

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
Free amino acids3.26%
Dipeptides23.19%
Tripeptides50.72%
Tetrapeptides22.10%
Pentapeptides0.72%

These are composition fractions of the complex, not AEDG concentration or bioavailability. Detection of AEDG does not make extract clinical results interchangeable with synthetic Epitalon.

Source for these results ↗ · Reviewed 2026-10-29

Population / setting
Pineal polypeptide-complex composition
Source reviewed
Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Study limitations
  • Detection in an extract does not prove that this peptide accounts for all extract effects.
  • Composition analysis does not establish clinical equivalence.

Reviewed 2026-09-29.

Read the source ↗

Comparison in people · 2003

Peptides of pineal gland and thymus prolong human life

The investigators reported differences in illness and mortality across extract-treatment groups and controls. This is research on Thymalin and Epithalamin, including their combination.

Study notes and original source
2003Human comparative studyEnglish abstract

Peptides of pineal gland and thymus prolong human life

Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology

Khavinson VKh, Morozov VG · Neuro Endocrinol Lett 24(3-4):233-240. PMID 14523363

The investigators reported differences in illness and mortality across extract-treatment groups and controls. This is research on Thymalin and Epithalamin, including their combination.

Results and tables

Reported findings and study design

266 older adults followed 6–8 years; Thymalin/Epithalamin used during the first 2–3 years. A separate annual-combination subgroup was treated for six years.

Population or model 266 older people followed for 6–8 years

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
Acute respiratory disease incidenceTwo- to 2.4-fold lower as reported
Mortality, Thymalin groupTwo- to 2.1-fold lower
Mortality, Epithalamin group1.6- to 1.8-fold lower
Mortality, combination group2.5-fold lower
Separate annual-combination subgroup mortality4.1-fold lower

Source abstract does not supply arm denominators, death counts or confidence intervals. Separate treatment schedules are not pooled and extract results are not assigned to synthetic peptides.

Source for these results ↗ · Reviewed 2026-10-29

Population / setting
266 older people followed for 6–8 years
Source reviewed
Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Study limitations
  • The abstract leaves group assignment, dropouts, baseline differences and outcome assessment unclear.
  • The outcomes concern the preparations used in this study. Independent replication and effects of Vilon, Thymogen and synthetic Epitalon remain uncertain.

Reviewed 2026-09-29.

Read the source ↗

Observational study · 2004

Effect of peptide preparation epithalamin on circadian rhythm of epiphyseal melatonin-producing function in elderly people

Reported changes in nighttime melatonin that differed according to baseline pineal activity.

Study notes and original source
2004Uncontrolled human reportEnglish abstract

Effect of peptide preparation epithalamin on circadian rhythm of epiphyseal melatonin-producing function in elderly people

Korkushko OV, Khavinson VKh, Shatilo VB, Magdich LV · Bull Exp Biol Med 137(4):389-391. PMID 15452611

Reported changes in nighttime melatonin that differed according to baseline pineal activity.

Population / setting
Older adults; plasma melatonin before and after treatment
Source reviewed
Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Study limitations
  • Before/after hormone measurements do not establish sleep-stage or clinical sleep benefit.
  • The preparation is Epithalamin, not isolated AEDG.

Reviewed 2026-09-29.

Read the source ↗

Randomized study in people · 2006

Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging

The abstract describes a randomized comparison and reports favorable long-term cardiovascular and mortality outcomes with the pineal extract.

All-cause deaths · 28% fewer in the treated group as reported

Study notes and original source
2006Randomized trialEnglish abstract

Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging

Korkushko OV, Khavinson VKh, Shatilo VB, Antonyuk-Shcheglova IA · Bull Exp Biol Med 142(3):356-359. PMID 17426848

The abstract describes a randomized comparison and reports favorable long-term cardiovascular and mortality outcomes with the pineal extract.

Results and tables

Reported findings and study design

Twelve-year report involving elderly coronary-disease patients, described as randomized; Epithalamin tissue extract plus basic care versus basic care.

Population or model Older patients with coronary disease and accelerated cardiovascular aging; 12-year follow-up

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
All-cause deaths28% fewer in the treated group as reported
Cardiovascular mortalityTwofold lower as reported
Cardiovascular failure and respiratory disease incidenceTwofold lower as reported

No sample size, event counts or confidence intervals are supplied in the abstract. These are Epithalamin extract findings, not synthetic Epitalon results.

Source for these results ↗ · Reviewed 2026-10-29

Population / setting
Older patients with coronary disease and accelerated cardiovascular aging; 12-year follow-up
Source reviewed
Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Study limitations
  • The abstract leaves group assignment and follow-up unclear and gives no absolute event counts.
  • Potential overlap with later follow-up reports must be checked; this is not an Epitalon trial.

Reviewed 2026-09-29.

Read the source ↗

Explore related historical combinations ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗